Erratum: Autophagy as a new therapeutic target in duchenne muscular dystrophy (Cell Death and Disease (2012) 3 (e418) DOI: 10.1038/cddis.2012.159);Autophagy as a new therapeutic target in Duchenne muscular dystrophy

Cell Death and Disease

Volumn 3, Issue 11, 2012, Pages

  De Palma, C ^a   Morisi, F ^b   Cheli, S ^a   Pambianco, S ^a   Cappello, V ^a,c   Vezzoli, M ^d   Rovere Querini, P ^d   Moggio, M ^a   Ripolone, M ^a   Francolini, M ^a   Sandri, M ^e   Clementi, E ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d San Raffaele Scientific InstituteMilano   (Italy)

^e VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Autophagy; Duchenne muscular dystrophy; Therapy

Indexed keywords

CHLOROQUINE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BNIP3; PROTEIN KINASE B; PROTEIN S6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATG12 GENE; AUTOPHAGY; BNIP3 GENE; CELL ORGANELLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GABARAPL1 GENE; GENE; HUMAN; HUMAN TISSUE; MICROTUBULE ASSOCIATED PROTEIN 1 LIGHT CHAIN 3 GENE; MOUSE; MUSCLE FUNCTION; MUSCLE INJURY; MYOFIBROSIS; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN RESTRICTION; SIGNAL TRANSDUCTION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 84870479343     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.72     Document Type: Erratum

References (48)

1. Emery AE. The muscular dystrophies. Lancet 2002; 359: 687-695.
2. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 2011; 19: 830-840.
3. Dubowitz V. Prednisone for Duchenne muscular dystrophy. Lancet Neurol 2005; 4: 264.
4. Muntoni F, Fisher I, Morgan JE, Abraham D. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscul Disord 2002; 12(Suppl 1): S162-S165.
5. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004; 306: 990-995.
6. Raben N, Hill V, Shea L, Takikita S, Baum R, Mizushima N et al. Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum Mol Genet 2008; 17: 3897-3908.
7. Sandri M. Autophagy in skeletal muscle. FEBS Lett 2010; 584: 1411-1416.
8. Masiero E, Agatea L, Mammucari C, Blaauw B, Loro E, Komatsu M et al. Autophagy is required to maintain muscle mass. Cell Metab 2009; 10: 507-515.
9. Vergne I, Roberts E, Elmaoued RA, Tosch V, Delgado MA, Proikas-Cezanne T et al. Control of autophagy initiation by phosphoinositide 3-phosphatase Jumpy. EMBO J 2009; 28: 2244-2258.
10. Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol 2009; 187: 859-874.
11. Grumati P, Coletto L, Sabatelli P, Cescon M, Angelin A, Bertaggia E et al. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration. Nat Med 2010; 16: 1313-1320.
12. Grumati P, Coletto L, Sandri M, Bonaldo P. Autophagy induction rescues muscular dystrophy. Autophagy 2011; 7: 426-428.
13. Dogra C, Changotra H, Wergedal JE, Kumar A. Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J Cell Physiol 2006; 208: 575-585.
14. Peter AK, Crosbie RH. Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. Exp Cell Res 2006; 312: 2580-2591.
15. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 458-471.
16. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007; 6: 472-483.
17. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008; 14: 442-447.
18. Culligan K, Banville N, Dowling P, Ohlendieck K. Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle. J Appl Physiol 2002; 92: 435-445.
19. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-752.
20. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007; 131: 1149-1163.
21. Mammucari C, Schiaffino S, Sandri M. Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy 2008; 4: 524-526.
22. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151-175.
23. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004; 15: 1101-1111.
24. Hegge JO, Wooddell CI, Zhang G, Hagstrom JE, Braun S, Huss T et al. Evaluation of hydrodynamic limb vein injections in nonhuman primates. Hum Gene Ther 2010; 21: 829-842.
25. Carlson CG, Makiejus RV. A noninvasive procedure to detect muscle weakness in the mdx mouse. Muscle Nerve 1990; 13: 480-484.
26. Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem 1995; 118: 959-964.
27. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009; 296: C1248-C1257.
28. Vessoni AT, Muotri AR, Okamoto OK. Autophagy in stem cell maintenance and differentiation. Stem Cells Dev 2012; 21: 513-520.
29. Homsher E, Kean CJ. Skeletal muscle energetics and metabolism. Annu Rev Physiol 1978; 40: 93-131.
30. Eghtesad S, Jhunjhunwala S, Little SR, Clemens PR. Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle. Mol Med 2011; 17: 917-924.
31. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3: 1014-1019.
32. Pallafacchina G, Calabria E, Serrano AL, Kalhovde JM, Schiaffino S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci USA 2002; 99: 9213-9218.
33. Pauly M, Daussin F, Burelle Y, Li T, Godin R, Fauconnier J et al. AMPK activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm. Am J Pathol 2012; 181: 583-592.
34. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-1522.
35. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012; 20: 443-455.
36. Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, Sewry C et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 2012; 20: 462-467.
37. Sciorati C, Miglietta D, Buono R, Pisa V, Cattaneo D, Azzoni E et al. A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol Res 2011; 64: 210-217.
38. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006; 12: 1147-1150.
39. Sciorati C, Buono R, Azzoni E, Casati S, Ciuffreda P, D'Angelo G et al. Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Br J Pharmacol 2010; 160: 1550-1560.
40. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG et al. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA 2007; 104: 264-269.
41. Fairclough RJ, Perkins KJ, Davies KE. Pharmacologically targeting the primary defect and downstream pathology in duchenne muscular dystrophy. Curr Gene Ther 2012; 12: 206-244.
42. D'Angelo MG, Gandossini S, Martinelli Boneschi F, Sciorati C, Bonato S, Brighina E et al. Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res 2012; 65: 472-479.
43. Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, Straino S et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 2008; 105: 19183-19187.
44. De Palma C, Clementi E. Nitric oxide in myogenesis and therapeutic muscle repair. Mol Neurobiol 2012; doi: 10.1007/s12035-012-8311.
45. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; CD003725; doi: 10.1002/14651858.
46. Sciorati C, Galvez BG, Brunelli S, Tagliafico E, Ferrari S, Cossu G et al. Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. J Cell Sci 2006; 119(Part 24): 5114-5123.
47. Deponti D, Francois S, Baesso S, Sciorati C, Innocenzi A, Broccoli V et al. Necdin mediates skeletal muscle regeneration by promoting myoblast survival and differentiation. J Cell Biol 2007; 179: 305-319.
48. Francolini M, Brunelli G, Cambianica I, Barlati S, Barbon A, La Via L et al. Glutamatergic reinnervation and assembly of glutamatergic synapses in adult rat skeletal muscle occurs at cholinergic endplates. J Neuropathol Exp Neurol 2009; 68: 1103-1115.